Zobrazeno 1 - 10
of 47
pro vyhledávání: '"Tom J. Parry"'
Autor:
Li Zhang, Robin Schwartz-Byrne, Steven Gertz, Matthew McGuire, Colleen Woodhouse, Brianna Powell, Min Wei, Chao Li, Clare B. Billing, Todd A. Verdoorn, Leslie Lam, Tom J. Parry, Benjamin Buller, Zheng Gang Zhang, David Poulsen, Michael Chopp
Publikováno v:
Stroke. 53:3455-3464
Background: Ischemic stroke affects about 700 000 patients per year in the United States, and to date, there are no effective pharmacological agents that promote recovery. Here, we studied the pharmacokinetics, pharmacodynamics, and efficacy of NTS-1
Autor:
Ariana P. Mullin, Charlene Cui, Yu Wang, Jing Wang, Erika Troy, Anthony O. Caggiano, Tom J. Parry, Raymond W. Colburn, Elias Pavlopoulos
Publikováno v:
Neurobiology of Disease, Vol 105, Iss , Pp 142-155 (2017)
Failure of oligodendrocyte precursor cells (OPCs) to differentiate and remyelinate axons is thought to be a major cause of the limited ability of the central nervous system to repair plaques of immune-mediated demyelination in multiple sclerosis (MS)
Externí odkaz:
https://doaj.org/article/78f35256590b494b885fdedcb8ce3242
Autor:
Michael F Hill, Amish V Patel, Abigail Murphy, Holly M Smith, Cristi L Galindo, Laura Pentassuglia, Xuyang Peng, Carrie G Lenneman, Oghenerukevwe Odiete, David B Friedman, Marvin W Kronenberg, Siyuen Zheng, Zhongming Zhao, Yanna Song, Frank E Harrell, Maya Srinivas, Anindita Ganguly, Jennifer Iaci, Tom J Parry, Anthony O Caggiano, Douglas B Sawyer
Publikováno v:
PLoS ONE, Vol 8, Iss 2, p e55741 (2013)
Recombinant Neuregulin (NRG)-1β has multiple beneficial effects on cardiac myocytes in culture, and has potential as a clinical therapy for heart failure (HF). A number of factors may influence the effect of NRG-1β on cardiac function via ErbB rece
Externí odkaz:
https://doaj.org/article/6ecd2547b5fc43149fdd21ebb39b5092
Autor:
Jing Wang, Raymond W. Colburn, Anthony O. Caggiano, Charlene Cui, Tom J. Parry, Elias Pavlopoulos, Ariana P. Mullin
Publikováno v:
Brain Research. 1694:73-86
Multiple sclerosis (MS) is a chronic, inflammatory demyelinating disease of the CNS. In addition to motor, sensory and visual deficits, MS is also characterized by hippocampal demyelination and memory impairment. We recently demonstrated that a recom
Autor:
Kimberly M. Freeman, Jennifer Iaci, Jonathan P. Jackson, Andrew Eisen, Ric Stanulis, Donald Button, Paul B. Watkins, Anthony O. Caggiano, Merrie Mosedale, Tom J. Parry, Kenneth R. Brouwer, Maya Srinivas
Publikováno v:
Toxicological Sciences. 161:401-411
GGF2 is a recombinant human neuregulin-1β in development for chronic heart failure. Phase 1 clinical trials of GGF2 were put on hold when transient elevations in serum aminotransferases and total bilirubin were observed in 2 of 43 subjects who recei
Autor:
Jing Wang, Charlene Cui, Yu Wang, Ariana P. Mullin, Erika L. Troy, Raymond W. Colburn, Tom J. Parry, Elias Pavlopoulos, Anthony O. Caggiano
Publikováno v:
Neurobiology of Disease, Vol 105, Iss, Pp 142-155 (2017)
Failure of oligodendrocyte precursor cells (OPCs) to differentiate and remyelinate axons is thought to be a major cause of the limited ability of the central nervous system to repair plaques of immune-mediated demyelination in multiple sclerosis (MS)
Autor:
J. Luis Guerrero, Anthony O. Caggiano, Douglas B. Sawyer, Erika L. Troy, Maya Srinivas, Ronald Zolty, Anindita Ganguly, Craig Hackett, Donald Button, Tom J. Parry, Andrea Vecchione, Jennifer Iaci
Publikováno v:
European Journal of Pharmacology. 796:76-89
Neuregulins are important growth factors involved in cardiac development and response to stress. Certain isoforms and fragments of neuregulin have been found to be cardioprotective. The effects of a full-length neuregulin-1β isoform, glial growth fa
Publikováno v:
Neurorehabilitation and Neural Repair. 31:387-396
Background. 4-Aminopyridine (4-AP) is a Food and Drug Administration–approved drug to improve motor function in people with multiple sclerosis. Preliminary results suggest the drug may act on intact neural circuits and not just on demyelinated ones
Autor:
Zhihong Huang, Jennifer Iaci, Tom J. Parry, Elias Pavlopoulos, JingMei Ren, Anthony O. Caggiano, Seth P. Finklestein
Publikováno v:
Journal of Neuroscience Research. 94:253-265
Cimaglermin (neuregulin 1β3, glial growth factor 2) is a neuregulin growth factor family member in clinical development for chronic heart failure. Previously, in a permanent middle cerebral artery occlusion (pMCAO) rat stroke model, systemic cimagle
Autor:
Grant T. Generaux, Donald Button, Ric Stanulis, Anthony O. Caggiano, Brett A. Howell, Diane M. Longo, Merrie Mosedale, Daniel J. Antoine, Tom J. Parry, Paul B. Watkins, Andrew Eisen, Scott Q. Siler, Jennifer Iaci
Publikováno v:
Longo, D M, Generaux, G T, Bengry-Howell, A, Siler, S Q, Antoine, D, Button, D, Caggiano, J A, Eisen, J A, Iaci, J, Stanulis, R, Parry, T, Mosedale, M & Watkins, P B 2017, ' Refining Liver Safety Risk Assessment : Application of Mechanistic Modeling and Serum Biomarkers to Cimaglermin Alfa (GGF2) Clinical Trials ', Clinical pharmacology and therapeutics, vol. 102, no. 6, pp. 961-969 . https://doi.org/10.1002/cpt.711
Clinical Pharmacology and Therapeutics
Clinical Pharmacology and Therapeutics
Cimaglermin alfa (GGF2) is a recombinant human protein growth factor in development for heart failure. Phase I trials were suspended when two cimaglermin alfa-treated subjects experienced concomitant elevations in serum aminotransferases and total bi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fdd70ea640db5a0d3acd2dc98e1dfc91
https://www.pure.ed.ac.uk/ws/files/55790946/Antoine_D_Refining_Liver_Safety....pdf
https://www.pure.ed.ac.uk/ws/files/55790946/Antoine_D_Refining_Liver_Safety....pdf